Novo Nordisk partners with telehealth companies to offer Wegovy at $499 per month, expanding access to weight-loss medication as regulatory changes restrict compounded alternatives.
At a Glance
- Novo Nordisk has partnered with telehealth providers Hims & Hers, LifeMD, and Ro to expand access to FDA-approved Wegovy
- The medication is available at $499 per month for self-paying patients through NovoCare Pharmacy, less than half the typical $1000 monthly cost
- Wegovy’s FDA label was expanded in 2024 to include reducing major cardiovascular events in adults with heart disease and obesity
- This move comes as compounding pharmacies face May 22 deadline to stop marketing semaglutide copies
Expanding Access to Weight-Loss Treatment
Pharmaceutical giant Novo Nordisk has announced strategic partnerships with multiple telehealth providers to increase access to its FDA-approved weight-loss medication Wegovy. The collaborations with Hims & Hers Health, LifeMD, and Ro will enable patients to obtain authentic semaglutide treatment through digital healthcare platforms at a significantly reduced price point of $499 per month for those without insurance coverage. This represents a major discount from the typical $1000 monthly cost that has been a substantial barrier for many of the estimated 100 million Americans living with obesity who could potentially benefit from the treatment.
The initiative follows Novo Nordisk’s launch of NovoCare Pharmacy in March 2025, which allows for direct-to-patient home shipments of Wegovy. Through these new telehealth partnerships, patients can access all doses of the medication and schedule regular deliveries, creating a simplified pathway to treatment that bypasses some of the traditional healthcare hurdles. This approach also addresses the stigma sometimes associated with obesity treatment by allowing patients to seek care from the privacy of their homes while still maintaining quality medical supervision.
Novo Nordisk is partnering with telehealth companies including Hims & Hers, LifeMD, and Ro to offer its popular weight-loss drug Wegovy to more US patients at a reduced price https://t.co/LNx8jG93ev
— Bloomberg (@business) April 29, 2025
The Changing Landscape of Weight-Loss Medications
Wegovy, which contains the active ingredient semaglutide, is the only FDA-approved version of this GLP-1 receptor agonist specifically indicated for weight management. The medication received additional validation in 2024 when the FDA expanded its label to include reducing the risk of major cardiovascular events in adults with heart disease who are obese or overweight. This dual benefit makes it particularly valuable for patients with multiple health concerns, as it can address both weight management and heart health simultaneously.
The timing of these partnerships is particularly significant as they coincide with regulatory changes affecting compounded versions of semaglutide. Larger compounding pharmacies face a deadline of May 22 to stop marketing semaglutide copies, while smaller facilities had to cease operations by April 22. These compounded alternatives had gained popularity during supply shortages, but with those shortages now largely resolved, Novo Nordisk is positioning its FDA-approved Wegovy as the safer, more reliable option for patients seeking weight-loss treatment.
Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring $NVO https://t.co/vZAEfjmOxE
— FirstWord Pharma (@fwpharma) April 29, 2025
Telehealth Integration and Market Strategy
Each telehealth partner is implementing the Wegovy offering slightly differently. Hims & Hers will provide a comprehensive bundle that includes the medication, 24/7 care, clinical support, and nutrition guidance starting at $599 per month. Ro will offer the base price of $499 monthly while providing additional services such as one-on-one coaching and educational content. This integrated approach ensures medication quality, patient safety, and continuity of care through real-time communication between telehealth providers and pharmacists.
The market response to these partnerships has been overwhelmingly positive. Shares of Hims & Hers increased by 23%, and Novo Nordisk’s stock rose by 4% following the announcement. The move is part of Novo Nordisk’s broader strategy to regain market share in the competitive obesity drug market, where rival pharmaceutical company Eli Lilly has made significant inroads with its weight-loss medication Zepbound (tirzepatide). Novo Nordisk has also partnered with CVS Health Corporation to give Wegovy preferred coverage status over Zepbound for insured customers beginning in July, further strengthening its market position.
For the millions of Americans struggling with obesity who may have found cost to be a prohibitive factor in accessing effective treatment, these partnerships represent a significant step toward making evidence-based weight management more accessible and affordable. As the healthcare industry continues to evolve, this integration of pharmaceutical innovation with telehealth convenience demonstrates how traditional healthcare barriers can be overcome through strategic collaboration.
​
